相关临床试验
39
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1875
进行中（未招募）
1
2.6%
已完成
17
43.6%
尚未招募
5
12.8%
暂停
1
2.6%
终止
3
7.7%
Unknown
10
25.6%
撤回
2
5.1%
暂无批准数据
- A first-of-its-kind meta-analysis of 574 men with oligometastatic prostate cancer demonstrates that metastasis-directed therapy significantly improves progression-free survival by 7.6 months compared to standard care alone. - The WOLVERINE study, published in The Lancet Oncology, provides the highest level of evidence to date supporting metastasis-directed therapy, primarily stereotactic body radiation therapy, for treating limited metastatic disease. - Patients receiving metastasis-directed therapy showed consistent benefits across multiple endpoints including radiographic progression-free survival and castration resistance-free survival, with no additional safety risks observed.
- Two phase 1-2 clinical trials demonstrate that fecal microbiota transplantation (FMT) combined with immune checkpoint inhibitors achieves impressive response rates of 80% in non-small cell lung cancer and 75% in melanoma patients. - FMT from healthy donors successfully engrafts beneficial bacteria while eliminating harmful species from patients' baseline microbiomes, with bacterial loss being more predictive of treatment response than donor strain acquisition. - Safety profiles vary significantly by treatment regimen, with dual checkpoint inhibition showing earlier onset of severe adverse events, particularly when patients receive FMT from Prevotella-rich donors. - Metabolomic analysis reveals that treatment responders maintain lower levels of immunosuppressive tryptophan pathway metabolites, suggesting FMT helps preserve an immune-permissive environment for cancer therapy.
- Canadian researchers launch Phase 1 trial of LND101, an oral fecal transplant therapy, targeting pancreatic cancer's dismal 10% five-year survival rate. - The innovative "poop pill" aims to modify tumor microbiome composition, potentially enhancing chemotherapy effectiveness in advanced pancreatic cancer patients. - Following success in melanoma, lung cancer, and renal cell carcinoma, the two-year trial will evaluate gut bacteria changes and immune responses in 20 patients.
